Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets
Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, Osler disease, primary polycythemia, polycythemia rubra vera or Vaquez disease, is the over production of red blood cells as a result of acquired mutations in an early blood-forming cell. Since these early blood-forming cells have the capability to form not only red cells, but also white cells and platelets, any combination of these cell lines may be affected. This condition develops slowly and may remain undetected for many years.
This report provides the current prevalent population for Polycythemia Vera across 27 Major Markets (USA, France, Germany, Italy, Spain, United Kingdom, Japan, Brazil, Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, Finland, India, Ireland, Mexico, Netherlands, Norway, Poland, Portugal, Republic of Korea, Sweden, Switzerland, Turkey ) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of Polycythemia Vera have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Polycythemia Vera include:
• Blood clots
• Splenomegaly
• Skin problems
• Peptic Ulcers
• Gout
• Myelofibrosis
• Myelodysplastic syndrome
• Acute myeloid leukaemia
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in the global Polycythemia Vera market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Polycythemia Vera and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Polycythemia Vera’s prevalent population.
• Identify sub-populations within Polycythemia Vera which require treatment.
• Gain an understanding of the specific markets that have the largest number of Polycythemia Vera disease patients.
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line prevalence for Polycythemia Vera
• Features of Polycythemia Vera patients
• Thrombosis Outcome
o Thrombotic Event History
o Packed Cell Volume (L/L)
o Prior Arterial Thrombosis
o Prior Venous Thrombosis
o Incident Thrombosis
o Incident Acute Leukaemia
o Acute Myocardial Infarction
o Angina
o Aspirin Therapy
o Chronic Heart Failure
o Cytoreductive Drug Exposure
o Deep Vein Thrombosis
o Erythromelalgia
o Hypertension
o Intermittent Claudication
o JAK2-V617F Mutation
o Myelofibrosis (SMF)
o Peripheral
o Pulmonary Embolism
o Splenomegaly
o Superficial Thrombophlebitis
o TIA/Stroke
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
• Prevalence of Polycythemia Vera, total (000s)
• Prevalence of Polycythemia Vera, males (000s)
• Prevalence of Polycythemia Vera, females (000s)
• Thrombosis outcome in PV patients, total (000s)
• Thrombotic Event History in PV patients, total (000s)
• Packed Cell Volume in PV patients, total (000s)
• PV patients with Prior Arterial Thrombosis, total (000s)
• PV patients with Prior Venous Thrombosis, total (000s)
• Incident Thrombosis in PV patients, total (000s)
• Incident Acute Leukaemia in PV patients, total (000s)
• PV patients with AMI, total (000s)
• PV patients with Angina, total (000s)
• PV patients with Aspirin Therapy, total (000s)
• PV patients with CHF, total (000s)
• PV patients with Cytoreductive Drug Exposure, total (000s)
• PV patients with DVT, total (000s)
• PV patients with Erythromelalgia, total (000s)
• PV patients with Hypertension, total (000s)
• PV patients with Intermittent Claudication, total (000s)
• PV patients with JAK2-V617F mutation, total (000s)
• PV patients with Myelofibrosis, total (000s)
• PV patients with Peripheral, total (000s)
• PV patients with Pulmonary Embolism, total (000s)
• PV patients with Splenomegaly, total (000s)
• PV patients with Superficial Thrombophlebitis, total (000s)
• PV patients with TIA/Stroke, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• USA Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Canada Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Canada Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• France Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• France Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Germany Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Germany Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Italy Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Italy Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Spain Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Spain Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• UK Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• UK Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Japan Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Japan Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Brazil Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Brazil Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Australia Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Australia Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Austria Prevalence of Acne Vulgaris by 5-yr age cohort, males (000s)
• Austria Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Belgium Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Belgium Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• China Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• China Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Czech Republic Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Czech Republic Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Denmark Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Denmark Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Finland Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Finland Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• India Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• India Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Ireland Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Ireland Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Mexico Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Mexico Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Netherlands Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Netherlands Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Norway Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Norway Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Poland Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Poland Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Portugal Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Portugal Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Republic of Korea Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Republic of Korea Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Sweden Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Sweden Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Switzerland Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Switzerland Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
• Turkey Prevalence of Polycythemia Vera by 5-yr age cohort, males (000s)
• Turkey Prevalence of Polycythemia Vera by 5-yr age cohort, females (000s)
+1 888 709 8757
Chat With Us